Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | HCK | P08631 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.34 |
| ▸ | PRKDC | P78527 | 2/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868755 | 0.74 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL601353 | 0.74 | PIK3C3 (0.41) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL14144231 | 0.74 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL174229 | 0.74 | DYRK1A (0.43) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL18554370 | 0.74 | OGA (0.39) | PIK3C3AHRDYRK1AKEAP1CYP1A2 | |
| SCHEMBL557352 | 0.74 | EGLN2 (0.39) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL3185174 | 0.74 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL557143 | 0.74 | SMN1; SMN2 (0.44) | L3MBTL1PIK3C3KEAP1CYP1A2KMT2A | |
| SCHEMBL20755769 | 0.74 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 | |
| SCHEMBL14826051 | 0.74 | PIK3C3 (0.51) | PIK3C3DYRK1AKEAP1CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778490-A | Synthesis method of (R) -7-amino imidazo [1,2-a ] tetrahydropyridine-2-carboxylic acid ethyl ester | 无锡福祈制药有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026088070-A1 | COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4722209-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Shenogen Pharma Group (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008124323-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | L3MBTL1 265/4885PIK3C3 612/4885AHR 464/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | L3MBTL1 2293/4885PIK3C3 3786/4885AHR 1632/4885 |
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | L3MBTL1 1700/4885PIK3C3 661/4885AHR 3814/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | L3MBTL1 4626/4885PIK3C3 3033/4885AHR 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.